Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study

Journal of Human Hypertension

Volumn 21, Issue 7, 2007, Pages 525-530

  Goyal, D ^a   Chong, A Y ^a   Watson, R L ^a   Prasad, N ^b   Watson, R D ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 34347383775     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002174     Document Type: Article

References (20)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, Ramipril on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153.
2. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, Heart Outcomes Prevention Evaluation (HOPE) Study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-2131.
3. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366:895-906.
4. Thuillez C, Richer C, Giudicelli JF. Pharmacokinetics, converting enzyme inhibition and peripheral arterial haemodynamics of ramipril in healthy volunteers. Am J Cardiol 1987; 59: 38D-44D.
5. Meyer BH, Muller FO, Badian M, Eckert HG, Hajdu P, Irmisch R et al Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987; 59: 33D-37D.
6. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, Kuan TS et al. Influence of renal function on the pharmacokinetics of ramipril (HOE498). Am J Cardiol 1987; 59: 70D-78D.
7. Schunkert H, Kindler J, Gassmann M, Lahn W, Irmisch R, Debusmann ER et al. Steady-state kinetics of ramipril in renal failure. J Cardiovasc Pharmacol 1989; 13: S52-S54.
8. The AIRE Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
9. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38: E28-e32.
10. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
11. Goyal D, MacFadyen RJ, Watson R, Lip GYH. Ambulatory blood pressure monitoring in heart failure: A systematic review. Eur J Heart Failure 2005; 7: 149-156.
12. Coats AJ, Conway J, Somers VK, Isea JE, Sleight P. Ambulatory pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther 1989; 3: 303-311.
13. White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J 2004; 148: 628-634.
14. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
15. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al, PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
16. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539-546.
17. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998; 47(9): 1501-1506.
18. Owens P, O'Brien E. Hypotension in patients with coronary disease: Can profound hypotensive events cause myocardial ischaemic events? Heart 1999; 82: 477-481.
19. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135.
20. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-857.